BioMarin's new launch Voxzogo could surprise investors and become a blockbuster brand: analyst

After a period of "stagnant" growth at BioMarin—as characterized by one analyst team—the drugmaker could be on the brink of its next big launch. The company's dwarfism drug Voxzogo already has its European approval in hand, and it's due for an FDA decision later this week.